[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercytokinemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercytokinemia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":24,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100453964","immune-modulation-by-exosomes-in-covid-19-100453964",false,"NCT05191381","Immune Modulation by Exosomes in COVID-19","Immune Modulation by Stem Cell Derived Exosomes in Critically Ill COVID-19","IMECOV19","Inclusion Criteria:\n\n* Critically ill COVID-19 patients with lung dysfunction\n* COVID-19 WHO severity degree \\>= 4, ARDS (WHO Definition 13 March 2020)\n* Body weight \\> 50 kg\n* Informed consent\n\nExclusion Criteria:\n\n* Pregnant or breast feeding women",true,"ALL","18 Years","90 Years",{"count":22,"type":23},40,"ESTIMATED","12 Months","OBSERVATIONAL","Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.",[28,29,30,31],"COVID-19","Critical Illness","Hypercytokinemia","Lung Fibrosis",[28,33,30,34,35,36,37,38],"Critical illness","Exosomes","Mesenchymal stem cells","Tissue reconstitution","Immune modulation","Sepsis","RECRUITING","2024-01-16",{"date":42,"type":43},"2024-01-17","ACTUAL",{"date":45,"type":43},"2021-12-22",{"date":47,"type":23},"2026-12-31",{"name":49,"class":50},"University of Ulm","OTHER"]